ANK2 and arrhythmogenic right ventricular cardiomyopathy: Interestingly, when these mice were treated with GSK-3β-inhibitor, a pharmacological activator of β-catenin, it prevented and partially reversed the ARVC phenotype found in these mice [27], providing a hopeful outlook on developing new therapies for patients with AnkB variant-driven ARVC.